인사이트
Insights From Our Experts
Articles
Incorporating Medical Science Liaisons Early and Often Amplifies Impact and Delivers Stronger Patient Outcomes
The distinctly crucial role Medical Science Liaisons (MSLs) play in the healthcare industry helps ensure success for all stakeholders involved in a patient’s treatment journey. MSLs play a significant role in bridging the gap between scientific…
Utilization of Indirect Treatment Comparison (ITC), External Control Arms (ECA) and Patient-Reported Outcome Measures (PROMs)
Health Technology Assessment (HTA) is crucial to assessing the effectiveness, safety and cost-effectiveness of healthcare interventions. Indirect Treatment Comparison (ITC) is one trend that has gained traction in the HTA space as a way to evaluate…
Digital Guide to Commercializing Complex Therapeutics
Pharmaceutical manufacturers specializing in Rare Disease, Oncology, Personalized Cancer Immunotherapy, and Cell and Gene therapies encounter a range of complex challenges, including advancements in medicine and technology, changing patient and provider needs, market access, regulatory pathways,…
Patient-centric Approach to Clinical Trial Support Leveraging Medical Information Services
The number of clinical studies conducted has steadily shown a significant increase year over year for the past two decades. However, the number of new drug and biologic approvals have not seen this same kind of…
Role of Decentralized Trials for Newer Drug Approvals
Decentralized clinical trials (DCTs) are an innovative approach to conducting clinical research where aspects of the trial are carried out remotely, allowing patients to participate from their homes or local healthcare facilities. DCTs offer several advantages…
Matching-Adjusted Indirect Comparison (MAIC): An Established Methodology for Comparing Treatment Efficacies Across Trials
In the realm of comparative effectiveness research (CER), decision-makers often face challenges when attempting to compare treatment efficacies due to limited availability of comparative data, especially for new therapies. This white paper introduces the Matching-Adjusted Indirect…
What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry
EVERSANA’s Value & Evidence (V&E) and Data & Analytics (D&A) team collectively had an impressive 27 abstracts accepted to ISPOR U.S. 2023, showcasing EVERSANA’s ability to cross-solve for clients’ HEOR needs. EVERSANA’s Value & Evidence and…
Establishing the Patient Access Mission During Clinical Development
An inescapable but disappointing characteristic of pharmaceutical research and development is that at the end of a process costing billions of dollars, the majority of launches fail to reach expectations. The ultimate tragedy of this is…
WEBINAR: A Pivotal Shift in Life Sciences Industry Across R&D and Commercial: A Conversation with the Experts
The life sciences pipeline is evolving from small molecules to biologics and cell and gene therapy, and there are currently more than 900 therapies in clinical trials. As competition rises, manufacturers also need to manage the…